What shareholders can do to beat the market with Halozyme Therapeutics Inc. (HALO) stock

In the latest session, Halozyme Therapeutics Inc. (NASDAQ: HALO) closed at 38.74 down -1.20% from its previous closing price of $39.21. In other words, the price has decreased by $-0.47 from its previous closing price. On the day, 1074566 shares were traded. HALO reached its highest trading level at $39.22 during the session, while it also had its lowest trading level at $38.22.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .



For a deeper understanding of Halozyme Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 25.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.55. For the most recent quarter (mrq), Quick Ratio is recorded 2.20 and its Current Ratio is at 2.70. In the meantime, Its Debt-to-Equity ratio is 4.25 whereas as Long-Term Debt/Eq ratio is at 3.91.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on September 09, 2022, initiated with a Overweight rating and assigned the stock a target price of $50.

On May 23, 2022, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $52.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 08 when Torley Helen sold 50,000 shares for $39.82 per share. The transaction valued at 1,990,768 led to the insider holds 537,160 shares of the business.

MATSUI CONNIE sold 32,000 shares of HALO for $1,292,113 on Nov 05. The Director now owns 181,983 shares after completing the transaction at $40.38 per share. On Oct 04, another insider, Torley Helen, who serves as the President and CEO of the company, sold 50,000 shares for $40.09 each. As a result, the insider received 2,004,390 and left with 537,160 shares of the company.

Valuation Measures:

As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.35, and their Forward P/E ratio for the next fiscal year is 12.50. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.50. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.04 while its Price-to-Book (P/B) ratio in mrq is 18.19.

Stock Price History:

Over the past 52 weeks, HALO has reached a high of $52.98, while it has fallen to a 52-week low of $31.36. The 50-Day Moving Average of the stock is 44.12, while the 200-Day Moving Average is calculated to be 40.77.

Shares Statistics:

For the past three months, HALO has traded an average of 1.43M shares per day and 1.5M over the past ten days. A total of 137.94M shares are outstanding, with a floating share count of 136.31M. Insiders hold about 0.20% of the company’s shares, while institutions hold 96.30% stake in the company. Shares short for HALO as of Jul 14, 2022 were 8.9M with a Short Ratio of 7.47, compared to 8.48M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 6.45% and a Short% of Float of 7.59%.

Earnings Estimates

There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0.5 for the current quarter, with a high estimate of $0.57 and a low estimate of $0.43, while EPS last year was $0.66. The consensus estimate for the next quarter is $0.58, with high estimates of $0.63 and low estimates of $0.54.

Analysts are recommending an EPS of between $2.59 and $2.08 for the fiscal current year, implying an average EPS of $2.23. EPS for the following year is $2.97, with 5 analysts recommending between $3.36 and $2.41.

Revenue Estimates

A total of 7 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $686.79M, while the lowest revenue estimate was $530.09M, resulting in an average revenue estimate of $610.87M. In the same quarter a year ago, actual revenue was $443.31M, up 37.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $799.34M in the next fiscal year. The high estimate is $914M and the low estimate is $671.9M. The average revenue growth estimate for next year is up 30.90% from the average revenue estimate for this year.